Safety of omalizumab in asthma
Authors:
- Ricardo A TanRTRicardo A Tan
- Jonathan CorrenJCJonathan Corren
- 15 March 2011
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 10 (3) , 463-471
Abstract
(2011). Safety of omalizumab in asthma. Expert Opinion on Drug Safety: Vol. 10, No. 3, pp. 463-471. doi: 10.1517/14740338.2011.563840Keywords
This publication has 38 references indexed in Scilit:
- Efficacy of omalizumab in the treatment of atopic dermatitis: A pilot studyAllergy and Asthma Proceedings, 2008
- Churg-Strauss Vasculitis in a Patient Treated with OmalizumabJournal of Asthma, 2008
- Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatmentJournal of Allergy and Clinical Immunology, 2008
- Safety of anti‐immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infectionClinical & Experimental Allergy, 2007
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthmaAllergy, 2004
- Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitisAnnals of Allergy, Asthma & Immunology, 2003
- Omalizumab is effective in the long-term control of severe allergic asthmaAnnals of Allergy, Asthma & Immunology, 2003
- Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitisJournal of Allergy and Clinical Immunology, 2002
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- OmalizumabDrugs, 2001